Featured Research

from universities, journals, and other organizations

Overexpression Of Fatty Acid Synthase Promotes Prostate Cancer In Mouse Models

Date:
April 2, 2009
Source:
Journal of the National Cancer Institute
Summary:
Fatty acid synthase (FASN) can act as a prostate cancer oncogene in mouse models.

Fatty acid synthase (FASN) can act as a prostate cancer oncogene in mouse models.

FASN, a key enzyme in the synthesis of long-chain fatty acids, is overexpressed in prostate cancer, relative to its expression in adjacent normal tissue. Additionally, previous studies showed that inhibition of FASN activity promoted programmed cell death in prostate cancer cell lines.

In the current study, Massimo Loda, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues overexpressed FASN in a variety of prostate cancer and precancerous cell lines.

Overexpression of FASN increased cell proliferation and substrate-independent growth. When immortalized prostate epithelial cells that expressed both FASN and the androgen receptor were injected into immunodeficient mice, the cells gave rise to invasive cancer. Inhibition of FASN gene expression led to programmed cell death in a prostate cancer cell line grown in culture. FASN expression showed an inverse correlation with the rate of programmed cell death in prostate cancer biopsy samples.

"The experimental evidence we provide on the oncogenic role of FASN in the prostate suggests that pharmacological targeting of FASN might represent an effective treatment for prostate cancer," the authors write.

The research is published in the March 24 online issue of the Journal of the National Cancer Institute.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Toshiro Migita, Stacey Ruiz, Alessandro Fornari, Michelangelo Fiorentino, Carmen Priolo, Giorgia Zadra, Fumika Inazuka, Chiara Grisanzio, Emanuele Palescandolo, Eyoung Shin, Christopher Fiore, Wanling Xie, Andrew L. Kung, Phillip G. Febbo, Aravind Subramanian, Lorelei Mucci, Jing Ma, Sabina Signoretti, Meir Stampfer, William C. Hahn, Stephen Finn, and Massimo Loda. Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. Journal of the National Cancer Institute, 2009; DOI: 10.1093/jnci/djp030

Cite This Page:

Journal of the National Cancer Institute. "Overexpression Of Fatty Acid Synthase Promotes Prostate Cancer In Mouse Models." ScienceDaily. ScienceDaily, 2 April 2009. <www.sciencedaily.com/releases/2009/03/090324215845.htm>.
Journal of the National Cancer Institute. (2009, April 2). Overexpression Of Fatty Acid Synthase Promotes Prostate Cancer In Mouse Models. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/03/090324215845.htm
Journal of the National Cancer Institute. "Overexpression Of Fatty Acid Synthase Promotes Prostate Cancer In Mouse Models." ScienceDaily. www.sciencedaily.com/releases/2009/03/090324215845.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins